{"id":"aramchol-free-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL5082715","moleculeType":"Unknown","molecularWeight":"398.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking SCD1, aramchol decreases the production of monounsaturated fatty acids in the liver, which reduces hepatic steatosis and improves insulin sensitivity. This mechanism addresses the underlying metabolic dysfunction in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), reducing liver fat accumulation and inflammation.","oneSentence":"Aramchol inhibits stearoyl-CoA desaturase 1 (SCD1), an enzyme that converts saturated fatty acids to monounsaturated fatty acids, thereby reducing hepatic lipogenesis and improving liver metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:16.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-alcoholic steatohepatitis (NASH)"},{"name":"Non-alcoholic fatty liver disease (NAFLD)"}]},"trialDetails":[{"nctId":"NCT04104321","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)","status":"SUSPENDED","sponsor":"Galmed Research and Development, Ltd.","startDate":"2019-09-23","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":157},{"nctId":"NCT06502561","phase":"PHASE1","title":"Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galmed Pharmaceuticals Ltd","startDate":"2025-02-15","conditions":"Healthy","enrollment":16},{"nctId":"NCT04480827","phase":"PHASE1","title":"Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment","status":"COMPLETED","sponsor":"Galmed Research and Development, Ltd.","startDate":"2020-02-13","conditions":"Hepatic Impairment","enrollment":57},{"nctId":"NCT05874336","phase":"PHASE1","title":"An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol","status":"COMPLETED","sponsor":"Galmed Pharmaceuticals Ltd","startDate":"2020-06-17","conditions":"NASH","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid","Two tablets of Aramchol free acid"],"phase":"phase_3","status":"active","brandName":"Aramchol free acid","genericName":"Aramchol free acid","companyName":"Galmed Pharmaceuticals Ltd","companyId":"galmed-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aramchol inhibits stearoyl-CoA desaturase 1 (SCD1), an enzyme that converts saturated fatty acids to monounsaturated fatty acids, thereby reducing hepatic lipogenesis and improving liver metabolism. Used for Non-alcoholic steatohepatitis (NASH), Non-alcoholic fatty liver disease (NAFLD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}